Exploring [18F]3F4AP for Demyelination Imaging
This study is looking at how a special imaging agent called [18F]3F4AP works in the body. We want to see if it can help us better understand conditions where the protective covering of nerves (myelin) is damaged, such as Multiple Sclerosis (MS), Alzheimer's Disease (AD), and Spinal Cord Injury (SCI). You might be able to join if you are between 18 and 90 years old and in good health. We will also compare [18F]3F4AP to two other imaging agents, [18F]MK6240 and [11C]PIB. The study aims to measure how these agents spread and bind in the body over 5 years. The study is currently unclear on its recruitment status.
- Study design
- This interventional study plans to enroll 105 participants. It involves giving participants different imaging agents for PET scans.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 5 years to measure how the imaging agents distribute and bind in the body.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Exploring the Utility of [18F]3F4AP for Demyelination Imaging
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Georges El Fakhri, PhD, DABR · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Tracers volume of distribution (VT)5 years
PET images measured with \[ 18F\]3F4AP will quantify demyelination, those obtained with \[18F\]MK6240 will quantify tau burden and those obtained with \[11C\]PiB will reflect amyloid burden. PET images acquired with \[18F\]3F4AP, \[18F\]MK6240 and \[11C\]PiB, will measure the tracers volume of distribution (VT).
- Distribution volume ratio (DVR)5 years
PET images acquired with \[18F\]3F4AP, \[18F\]MK6240 and \[11C\]PiB, will measure the tracers distribution volume ratio (DVR).
- Binding potential (BPND)5 years
PET images acquired with \[18F\]3F4AP, \[18F\]MK6240 and \[11C\]PiB, will measure the tracers binding potential (BPND).
- Demyelination5 years
\[18F\]3F4AP will be used to measure demyelination. On the MR images, after co-registration and alignment, signal from pre- and post-contrast T1-weighted images, T2-weighted image, ratio between T1- and T2-weighted images (T1/T2) will be calculated to assess demyelination and white matter lesion (WML) on MR sequences.
- Tau burden5 years
\[18F\]MK6240 will be used to measure Tau burden.
- Amyloid burden5 years
\[11C\]PiB will reflect amyloid burden.
- Tracer rate constant5 years
The tracer rate constant for transfer from arterial plasma to tissue K1 and relative delivery R1 will also be estimated using tracer kineticmodeling technique, to provide measures of cerebral perfusion or CBF.
- Associations between imaging modalities and biomarkers.5 years
The Pearson correlation coefficient r will be used to assess the strength of the linear correlations between outcome measures. A P value of 0.05 or less will be considered statistically significant.